World
Oramed Pharmaceuticals Granted Australian Patent for Important Part of the Company's Core Technology in Oral Delivery of Proteins
By
Jan 24, 2012 - 9:33:36 AM

(HealthNewsDigest.com) - JERUSALEM, January 24, 2012 -- Marking a major milestone for the Company, Oramed Pharmaceuticals Inc. (OTCBB: ORMP)
, a developer of oral drug delivery systems, announced today that it has received approval for
a key patent by the Australian Patent Office. The patent covers an important part of the Company's core technology which allows for the oral delivery of peptides. Oramed's portfolio now consists of one issued patent and 34 patents pending for its technologies and products.

Oramed's core product is an oral insulin capsule. An oral delivery system for insulin
may increase patient value, leading to a healthier lifestyle, especially at the earliest
of stages of diabetes treatment. Higher patient compliance may result in improved patient
outcomes and a reduction in the costs of healthcare and lost productivity.

According to a report by Medtech Insight, diabetes affects nearly 24 million people in
the U.S. and an estimated 246 million adults worldwide. Being one of the most expensive
diseases, it costs the US healthcare system more than $130 billion per year and the market
for direct pharmaceutical care is close to $15 billion.

"Our patent position further strengthens Oramed and our competitive advantage in the
development of an oral insulin capsule. The patent received will provide additional
commercial protection for Oramed's technology and adds extended value to our existing
IP-portfolio," said Nadav Kidron, CEO of Oramed.

(http://www.oramed.com
[http://us.lrd.yahoo.com/SIG=11adsmcif/EXP=1326899031/**http%3A/www.oramed.com ])

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions
for drugs and vaccines presently delivered via injection. Oramed is seeking to
revolutionize the treatment of diabetes through its patented flagship product, an orally
ingestible insulin capsule currently in phase 2 clinical trials. Established in 2006,
Oramed's technology is based on over 25 years of research by top research scientists at
Jerusalem's Hadassah Medical Center. The Company's corporate and R&D headquarters are
based in Jerusalem. For more information, please visit http://www.oramed.com
[http://us.lrd.yahoo.com/SIG=11adsmcif/EXP=1326899031/**http%3A/www.oramed.com ]

###

For advertising and promotion on HealthNewsDigest.com please contact Mike McCurdy: tvmike13@HealthNewsDigest.com or 877-634-9180
HealthNewsDigest.com is syndicated worldwide and has over 7,000 journalists as subscribers.
www.HealthNewsDigest.com

© Copyright by HealthNewsDigest.com